Prospect and progress of gene therapy in acute intermittent porphyria

References

• Beukeveld GJ, Wolthers BG, Nordmann Y, et al. A retrospective study of a patient with homozygous form of acute intermittent porphyria. J Inherit Metab Dis. 1990;13:673–683.
   PubMed Web of Science ®Google Scholar
• Brancaleoni V, Granata F, Colancecco A, et al. Seven novel genetic mutations within the 5’UTR and the housekeeping promoter of HMBS gene responsible for the non-erythroid form of acute intermittent porphyria. Blood Cells Mol Dis. 2012;49:147–151.
   PubMed Web of Science ®Google Scholar
• Gonzaga AD, De Amorim LM, Fonseca AB, et al. Hydroxymethylbilane synthase gene mutations and polymorphisms in Brazilian families with acute intermittent porphyria. Ann Hum Genet. 2015;79:162–172.
   PubMed Web of Science ®Google Scholar
• Szlendak U, Lipniacka A, Bianketti J, et al. Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria. Adv Clin Exp Med. 2015;24:63–68.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang H, Yin K, et al. A novel mutation in the porphobilinogen deaminase gene in an extended Chinese family with acute intermittent porphyria. Gene. 2015;565:288–290.
   PubMed Web of Science ®Google Scholar
• Ulbrichova D, Hrdinka M, Saudek V, et al. Acute intermittent porphyria–impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. Febs J. 2009;276:2106–2115.
   PubMed Web of Science ®Google Scholar
• Elder G, Harper P, Badminton M, et al. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36:849–857.
   PubMed Web of Science ®Google Scholar
• Bylesjo I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest. 2009;69:612–618.
   PubMed Web of Science ®Google Scholar
• Schuurmans MM, Schneider-Yin X, Rufenacht UB, et al. Influence of age and gender on the clinical expression of acute intermittent porphyria based on molecular study of porphobilinogen deaminase gene among Swiss patients. Mol Med. 2001;7:535–542.
   PubMed Web of Science ®Google Scholar
• Ramanujam VM, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc Hum Genet. 2015;86:17.20.1,17.20.26.
   PubMedGoogle Scholar
• Roveri G, Nascimbeni F, Rocchi E, et al. Drugs and acute porphyrias: reasons for a hazardous relationship. Postgrad Med. 2014;126:108–120.
   PubMed Web of Science ®Google Scholar
• Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201–214.
   PubMedGoogle Scholar
• Willandt B, Langendonk JG, Biermann K, et al. Liver fibrosis associated with iron accumulation due to long-term heme-arginate treatment in acute intermittent porphyria: a case series. JIMD Rep. 2015;25:77–81.
   PubMedGoogle Scholar
• Whatley SD, Badminton MN. Acute intermittent porphyria. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington;2005 Sep 27. p. 1993–2015. [updated 2013 Feb 7].1993.
   Google Scholar
• Anderson KE, Spitz IM, Sassa S, et al. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med. 1984;311:643–645.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Vicente JJ, Vanrell JA. Use of gonadotropin-releasing hormone analog with tibolone to prevent cyclic attacks of acute intermittent porphyria. Metabolism. 2001;50:995–996.
   PubMed Web of Science ®Google Scholar
• Innala E, Backstrom T, Bixo M, et al. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand. 2010;89:95–100.
   PubMed Web of Science ®Google Scholar
• Singal AK, Parker C, Bowden C, et al. Liver transplantation in the management of porphyria. Hepatology. 2014;60:1082–1089.
   PubMed Web of Science ®Google Scholar
• Yasuda M, Erwin AL, Liu LU, et al. Liver transplantation for acute intermittent porphyria: biochemical and pathologic studies of the explanted liver. Mol Med. 2015;21:487–495.
   PubMed Web of Science ®Google Scholar
• Dowman JK, Gunson BK, Mirza DF, et al. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl. 2012;18:195–200.
   PubMed Web of Science ®Google Scholar
• Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet. 2004;363:705–706.
   PubMed Web of Science ®Google Scholar
• Popescu I, Dima SO. Domino liver transplantation: how far can we push the paradigm? Liver Transpl. 2012;18:22–28.
   PubMed Web of Science ®Google Scholar
• Frei P, Minder EI, Corti N, et al. Liver transplantation because of acute liver failure due to heme arginate overdose in a patient with acute intermittent porphyria. Case Rep Gastroenterol. 2012;6:190–196.
   PubMedGoogle Scholar
• Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 2005;11:1100–1106.
   PubMed Web of Science ®Google Scholar
• Herrero JI, Lorenzo M, Quiroga J, et al. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 2005;11:89–97.
   PubMed Web of Science ®Google Scholar
• Watt KD. Keys to long-term care of the liver transplant recipient. Nat Rev Gastroenterol Hepatol. 2015;12:639–648.
   PubMed Web of Science ®Google Scholar
• Unzu C, Sampedro A, Mauleon I, et al. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J Hepatol. 2010;52:417–424.
   PubMed Web of Science ®Google Scholar
• Yin Z, Wahlin S, Ellis EC, et al. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Cell Transplant. 2014;23:1153–1162.
   PubMed Web of Science ®Google Scholar
• Johansson A, Moller C, Gellerfors P, et al. Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells. Scand J Clin Lab Invest. 2002;62:105–113.
   PubMed Web of Science ®Google Scholar
• Johansson A, Moller C, Harper P. Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery. Mol Cell Biochem. 2003;250:65–71.
   PubMed Web of Science ®Google Scholar
• Johansson A, Nowak G, Moller C, et al. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria. Mol Genet Metab. 2004;82:20–26.
   PubMed Web of Science ®Google Scholar
• Johansson A, Nowak G, Moller C, et al. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Mol Ther. 2004;10:337–343.
   PubMed Web of Science ®Google Scholar
• Unzu C, Sampedro A, Mauleon I, et al. Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice. Hum Mol Genet. 2013;22:2929–2940.
   PubMed Web of Science ®Google Scholar
• Unzu C, Sampedro A, Mauleon I, et al. Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol Ther. 2011;19:243–250.
   PubMed Web of Science ®Google Scholar
• Yasuda M, Bishop DF, Fowkes M, et al. AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function. Mol Ther. 2010;18:17–22.
   PubMed Web of Science ®Google Scholar
• Lisowski L, Tay SS, Alexander IE. Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol. 2015;24:59–67.
   PubMed Web of Science ®Google Scholar
• Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther. 2013;13:434–452.
   PubMed Web of Science ®Google Scholar
• Paneda A, Lopez-Franco E, Kaeppel C, et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther. 2013;24:1007–1017.
   PubMed Web of Science ®Google Scholar
• D’Avola D, Lopez-Franco E, Sangro B, et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol. Forthcoming.
   Google Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342–347.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357–2365.
   PubMed Web of Science ®Google Scholar
• Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47:1187–1193.
   PubMed Web of Science ®Google Scholar
• Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015;125:870–880.
   PubMed Web of Science ®Google Scholar
• Gil-Farina I, Käppel C, Wilkening S, et al. Improving AAV gene therapy safety analysis: multiplex LAM-PCR provide new insights into AAV vector integration. Mol. Ther. Forthcoming 2016.
   Web of Science ®Google Scholar
• Bell P, Moscioni AD, McCarter RJ, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther. 2006;14:34–44.
   PubMed Web of Science ®Google Scholar
• Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117:3311–3319.
   PubMed Web of Science ®Google Scholar
• Yasuda M, Gan L, Chen B, et al. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A. 2014;111:7777–7782.
   PubMed Web of Science ®Google Scholar
• Chan A, Liebow A, Yasuda M, et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acids. 2015;4:e263.
   PubMedGoogle Scholar
• Sardh E, Harper P, Al-Tawil N, et al. A Randomized, Placebo Controlled, Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic Targeting ALAS1. International Congress on Porphyrins and Porphyrias 2015, taking place in Düsseldorf. Germany; 2015. Available from: http://www.alnylam.com/web/assets/ALN-AS1_ICPP_Interim-Ph1_09152015.pdf
   Google Scholar
• Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32:551–553.
   PubMed Web of Science ®Google Scholar
• Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011;475:217–221.
   PubMed Web of Science ®Google Scholar
• http://investors.bmrn.com/releasedetail.cfm?ReleaseID=965945
   Google Scholar
• Nair J, Willoughby J, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and Elicits Robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136:16958–16961.
   PubMed Web of Science ®Google Scholar